Is nephrogenic systemic fibrosis linked to the introduction of contrast-enhanced MR angiography?

Radiology

Volumn 251, Issue 2, 2009, Pages 612-613

  Gossner, Johannes ^a  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; CHELATING AGENT; DIAGNOSTIC AGENT;

CONTRAST ENHANCEMENT; HUMAN; IMAGE QUALITY; INCIDENCE; LETTER; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; ADOLESCENT; ADULT; AGED; COMORBIDITY; KIDNEY FAILURE; METHODOLOGY; MIDDLE AGED; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICS; SYNDROME; SYSTEMIC SCLEROSIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHELATING AGENTS; COMORBIDITY; GADOLINIUM; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEW YORK; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; SYNDROME;

EID: 66149150200     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2512082246     Document Type: Letter

References (5)

1. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248(3):807-816.
2. Krause U, Kroencke T, Spielhaupter E, et al. Contrast-enhanced magnetic resonance angiography of the lower extremities: standard-dose vs. high-dose gadodiamide injection. J Magn Reson Imaging 2005;21(4):449-454.
3. Creasy JL, Price RR, Presbrey T, Goins D, Partain CL, Kessler RM. Gadolinium-enhanced MR angiography. Radiology 1990;175(1):280-283.
4. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000;356(9234):1000-1001.
5. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic systemic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.